cytidine monophosphate has been researched along with 1-arabinofuranosylcytosine-5'-stearylphosphate in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.64) | 18.7374 |
| 1990's | 41 (74.55) | 18.2507 |
| 2000's | 10 (18.18) | 29.6817 |
| 2010's | 2 (3.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirano, M; Imai, K; Kosaka, M; Mizoguchi, H; Nakamura, T; Ohno, R; Takatsuki, K; Tatsumi, N; Toyama, K; Yamaya, T | 1 |
| Furukawa, Y; Hiyoshi, M; Im, T; Inoue, K; Kishida, T; Nakao, Y; Ohira, H; Ota, K; Yamane, T; Yasui, Y | 1 |
| Arakawa, M; Ekimoto, H; Nagahata, T; Takahashi, K; Uchida, T | 1 |
| Deguchi, K; Kageyama, S; Komada, F; Minami, N; Morita, K; Nishikawa, M; Shirakawa, S; Uemura, Y | 1 |
| Fukuoka, M; Hattori, M; Hirota, Y; Miyazaki, T; Nakamura, T; Niitani, H; Ohta, K; Suzuoki, Y; Tanaka, M; Yoshida, Y | 1 |
| Kimura, I; Kimura, K; Masaoka, T; Nakamura, T; Ohno, R; Ohshima, T; Tatsumi, N; Yamada, K | 1 |
| Imamura, S; Kamiya, K; Kawai, Y; Nakamura, T; Tsutani, H; Ueda, T; Wano, Y | 1 |
| Higashigawa, M; Hori, H; Kawasaki, H; Ohkubo, T; Sakurai, M; Yoshizumi, T | 1 |
| Suga, T; Takayama, H; Watanabe, T; Yamada, J; Yoshida, Y | 1 |
| Arakawa, M; Ekimoto, H; Ishii, T; Kusama, K; Nagahata, T; Shibasaki, C; Takahashi, K; Uchida, T | 1 |
| Kodama, K; Kuninaka, A; Morozumi, M; Saitoh, K; Saneyoshi, M; Yoshino, H | 1 |
| Kamiya, K; Nakamura, T; Sugiyama, M; Tanaka, T; Tsutani, H; Ueda, T; Wano, Y | 1 |
| Arimori, K; Fujiwara, H; Fukuda, R; Kawada, H; Masumoto, A; Ogawa, Y; Ohbayashi, Y; Sasao, T; Umeda, Y; Watanabe, S | 1 |
| Furuyama, K; Harigae, H; Ishizawa, K; Kadowaki, I; Kimura, J; Nomura, J; Okuda, M; Sasaki, O; Sasaki, T; Shishido, T | 1 |
| Ekimoto, H; Iizuka, E; Koga, K; Okada, M; Sato, A | 1 |
| Arie, Y; Hirai, M; Kikukawa, M; Kodo, H; Kumakawa, T; Mizutani, R; Mori, M; Murai, Y; Nakamura, N; Tsutsumi, H | 1 |
| Braess, J; Hiddemann, W; Kaufmann, C; Ramsauer, B; Schleyer, E; Schüssler, M; Unterhalt, M; Wilde, S | 1 |
| Amano, T; Chinen, Y; Hamaoka, R; Imai, Y; Itoh, H; Jozaki, K; Kurokawa, M; Nishikawa, M; Yonezawa, T | 1 |
| Abe, T; Fukumi, S; Matsuo, A; Mizorogi, F; Sato, H | 1 |
| Braess, J; Hiddemann, W; Kaufmann, CC; Ramsauer, B; Schleyer, E; Unterhalt, M | 1 |
| Harada, M; Isokawa, M; Kimura, F; Kojima, K; Ohmoto, E; Takaba, S; Takeuchi, M; Tanimizu, M | 1 |
| Mori, N; Murakami, S; Nagata, K; Nakanishi, M; Nakata, K; Ogawa, R; Serino, Y; Takazawa, A; Tonai, S; Wake, A | 1 |
| Arai, T; Araki, M; Hayakawa, K; Narimiya, S; Shibuya, C; Takaya, T; Toshima, S; Uchida, A; Yasuda, Y; Yoshimi, N | 1 |
| Iwabe, K; Kitazume, K; Okuyama, Y; Urabe, A; Usuki, K | 1 |
| Niitsu, N; Shikoshi, K; Takada, M; Umeda, M | 1 |
| Fujita, N; Goto, H; Hirata, T; Inaba, T; Miyazaki, S; Nakagawa, M; Shimazaki, C; Tatsumi, T; Yamagata, N | 1 |
| Kamiya, K; Kawai, Y; Nakamura, T; Sugiyama, M; Tsutani, H; Ueda, T; Urasaki, Y; Wataya, S | 1 |
| Cao, DC; Higashigawa, M; Ido, M; Inamochi, H; Kagawa, Y; Kakitou, H; Matsui, K; Sakurai, M; Yamada, S | 1 |
| Tsukagoshi, S | 2 |
| Kitaori, K; Morishima, Y; Naito, K | 1 |
| Andoh, K; Fujimoto, H; Funasako, M; Hata, N; Itoh, K; Itoh, Y; Nakai, S; Nishi, T; Ohata, M; Ono, H; Sato, H; Sato, Y; Taniji, M; Ueda, A | 1 |
| Higa, T; Kasai, M; Kiyama, Y; Kobayashi, N; Masauzi, N; Naohara, T; Ogasawara, M; Ohizumi, H; Saito, M; Suzuki, G | 1 |
| Braess, J; Hiddemann, W; Kaeser-Fröhlich, A; Kaufmann, CC; Kern, W; Ramsauer, B; Schleyer, E; Schüssler, M; Unterhalt, M | 1 |
| Endo, M; Iki, S; Ito, K; Kitazume, K; Urabe, A; Usuki, K | 1 |
| Chuhjo, T; Katoh, T; Kaya, H; Matano, S; Matsuda, T; Murashima, M; Nakamura, S; Ohtake, S; Okumura, H; Takamatsu, H; Takeshima, M; Watanabe, A; Yamauchi, H; Yoshida, T | 1 |
| Miyazawa, J; Sakata, Y; Suto, K; Suto, T; Watanabe, Y; Yoshida, Y | 1 |
| Hayashi, Y; Imanaka, F; Shindo, H; Takimoto, Y | 1 |
| Fujisawa, S; Matsui, H; Yano, K | 1 |
| Azuma, T; Hara, M; Kojima, K; Narumi, H; Shinagawa, K | 1 |
| Ito, T; Konishi, H; Maesako, Y; Mori, S; Ueda, Y; Yagiri, Y | 1 |
| Braess, J; Freund, M; Hanauske, A; Heil, G; Hiddemann, W; Kaufmann, C; Kern, W; Schleyer, E; Schüssler, M | 1 |
| Chida, N; Ono, T; Oohira, H; Sakata, Y; Suto, T; Yamada, N; Yoshida, T; Yoshida, Y | 1 |
| Apfelbeck, U; Barbieri, G; Bechter, O; Duba, C; Eisterer, W; Gastl, G; Geissler, K; Kühr, T; Linkesch, W; Thaler, J; Zabernigg, A | 1 |
| Berger, U; Hehlmann, R; Hochhaus, A; Kuhn, C; Reiter, A | 1 |
| Antich, JL; Borrego, D; Brunet, S; Cervantes, F; Hernández-Boluda, JC; Martino, R; Montserrat, E; Sureda, A | 1 |
| del Cañizo, MC; Fisac, MP; Galende, J; Hurtado, JA; Moro, MJ; Rivas, JM; Rodriguez, JA; Tabernero, MD | 1 |
| Gotoh, A; Kawakubo, K; Kuriyama, Y; Miyazawa, K; Ohyashiki, K; Sashida, G; Uchida, Y | 1 |
| Abgrall, JF; Attal, J; Bauduer, F; Belhadj, K; Blanc, M; Brière, J; Cambier, N; Chabin, M; Chastang, C; Coso, D; Delain, M; Guerci, A; Guilhot, F; Guilhot, J; Guyotat, D; Harousseau, JL; Ifrah, N; Maloisel, F; Michallet, M; Morice, P; Pegourie-Bandelier, B; Reiffers, J; Rousselot, P; Solary, E; Tertain, G; Vilque, JP | 1 |
| Arkoumani, E; Bourantas, K; Kalambokis, G; Kitsanou, M; Stefanou, D; V Tsianos, E | 1 |
| Arthur, C; Blacklock, H; Bradstock, K; Browett, P; Coulston, J; Gibson, J; Grigg, A; Hawkins, T; Herrmann, R; Hughes, T; Januszewicz, H; Low, C; Martin, N; Mollee, P; Morton, J; Rodwell, R; Schwarer, AP; Seldon, M; Seymour, JF; Shina, S; Spencer, A; Taylor, D; Taylor, KM; Watson, A; Wolf, M; Wright, S | 1 |
| Chiba, S; Fukayama, M; Goyama, S; Inoue, M; Izutsu, K; Kako, S; Kanda, Y; Kurokawa, M; Motokura, T; Noda, N; Oshima, K; Sato, T; Shoda, E; Watanabe, T | 1 |
| Horikoshi, A; Hosokawa, Y; Sawada, S; Takei, K | 1 |
| Hatta, Y; Hirabayashi, Y; Horikoshi, A; Iriyama, N; Kobayashi, S; Kodaira, H; Matsukawa, Y; Miura, K; Takahashi, H; Takeuchi, J; Uchino, Y | 1 |
| Arahata, M; Asakura, H; Nakao, S; Shimizu, Y | 1 |
2 review(s) available for cytidine monophosphate and 1-arabinofuranosylcytosine-5'-stearylphosphate
| Article | Year |
|---|---|
[Recent development of antitumor antimetabolites in Japan--cytosine arabinoside analogues].
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleotides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Cytidine Monophosphate; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation | 1997 |
AraC-based pharmacotherapy of chronic myeloid leukaemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Clinical Trials as Topic; Cytarabine; Cytidine Monophosphate; Drug Administration Schedule; Guidelines as Topic; Humans; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Survival Analysis | 2001 |
17 trial(s) available for cytidine monophosphate and 1-arabinofuranosylcytosine-5'-stearylphosphate
| Article | Year |
|---|---|
Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate.
Topics: Adult; Aged; Aged, 80 and over; Arabinonucleotides; Cytidine Monophosphate; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1991 |
[Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Myelodysplastic Syndromes; Nausea; Vomiting | 1990 |
[Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Drug Evaluation; Female; Humans; Japan; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Nausea; Remission Induction; Vomiting | 1990 |
Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Topics: Administration, Oral; Antineoplastic Agents; Arabinofuranosyluracil; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Dose-Response Relationship, Drug; Half-Life; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Statistics, Nonparametric | 1995 |
[Treatment of refractory hematologic malignancies by combination of cytarabine ocfosfate and etoposide].
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia; Male; Middle Aged | 1996 |
Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Arabinonucleotides; Cytidine Monophosphate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prodrugs | 1996 |
Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1997 |
The effect of YNK-01 (an oral prodrug of cytarabine) on hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arabinonucleotides; Carcinoma, Hepatocellular; Cytidine Monophosphate; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prodrugs; Tomography, X-Ray Computed | 1997 |
[A combination chemotherapy with cytarabine ocfosfate, low dose etoposide, and G-CSF for the treatment of high risk MDS (RAEB, RAEBt)--a pilot study].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Bone Marrow; Cytidine Monophosphate; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Pilot Projects; Risk | 1998 |
[A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Time Factors | 1998 |
Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
Topics: Acute Disease; Administration, Oral; Adult; Antineoplastic Agents; Arabinonucleotides; Biological Availability; Cytarabine; Cytidine Monophosphate; Diarrhea; Dose-Response Relationship, Drug; Half-Life; Humans; Infusions, Intravenous; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Prodrugs; Regression Analysis | 1998 |
[Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Anemia; Anorexia; Antineoplastic Agents; Arabinonucleotides; Carcinoma, Hepatocellular; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Thrombocytopenia | 1998 |
Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pilot Projects; Recombinant Proteins; Treatment Outcome | 2000 |
Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Treatment Outcome | 2001 |
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prognosis; Recombinant Proteins; Risk Factors; Survival Rate | 2002 |
Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 2004 |
The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local | 2008 |
36 other study(ies) available for cytidine monophosphate and 1-arabinofuranosylcytosine-5'-stearylphosphate
| Article | Year |
|---|---|
[Clinical effects of stearyl-ara-CMP (YNK-01) on chronic hematologic malignancies].
Topics: Adult; Aged; Antineoplastic Agents; Arabinonucleotides; Chronic Disease; Cytidine Monophosphate; Drug Evaluation; Female; Humans; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Remission Induction | 1991 |
[Experimental combination chemotherapy of YNK01, a novel analog of cytarabine, with other antitumor agents].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cisplatin; Cytidine Monophosphate; Cytosine Nucleotides; Daunorubicin; Doxorubicin; Drug Synergism; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Mercaptopurine; Mice; Mice, Inbred DBA; Mitomycin; Mitomycins; Vincristine | 1990 |
[A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
Topics: Acute Disease; Administration, Oral; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukemia; Middle Aged; Prodrugs; Remission Induction | 1990 |
Successful treatment of myelodysplastic syndrome with 1-beta-D-arabinofuranosylcytosine 5'-stearylphosphate.
Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1990 |
Deoxyribonucleoside triphosphate pools and Ara-CTP levels in P388 murine leukemic cells treated with 1-B-D-arabinofuranosylcytosine-5'-stearylphosphate which is a newly synthesized derivative of 1-B-D-arabinofuranosylcytosine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Chromatography, High Pressure Liquid; Cytarabine; Cytidine Monophosphate; Deoxyribonucleotides; Leukemia P388; Male; Mice | 1990 |
Participation of the peroxisomal beta-oxidation system in the chain-shortening of PCA16, a metabolite of the cytosine arabinoside prodrug, YNKO1, in rat liver.
Topics: Animals; Arabinonucleotides; Cells, Cultured; Clofibrate; Coenzyme A Ligases; Cytarabine; Cytidine Monophosphate; Cytosine Nucleotides; Hydrogen Peroxide; Ketone Bodies; Liver; Microbodies; Mitochondria, Liver; Palmitates; Prodrugs; Rats; Rats, Inbred Strains; Repressor Proteins; Saccharomyces cerevisiae Proteins | 1990 |
[Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Cytosine Nucleotides; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Injections, Intraperitoneal; Injections, Intravenous; Leukemia L1210; Male; Mice; Neoplasms, Experimental; Tumor Cells, Cultured | 1990 |
Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Cytosine Nucleotides; Drug Administration Schedule; Leukemia L1210; Metabolic Clearance Rate; Mice; Solubility; Structure-Activity Relationship | 1989 |
[Pharmacokinetics of stearyl-ara-CMP (YNK-01) in patients with hematologic neoplasms].
Topics: Acute Disease; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Cytosine Nucleotides; Drug Evaluation; Humans; Leukemia; Myelodysplastic Syndromes | 1989 |
[Effects of cytarabine ocfosfate on colony-stimulating factor in myelodysplastic syndrome with monosomy 7].
Topics: Adult; Arabinonucleotides; Chromosomes, Human, Pair 7; Cytidine Monophosphate; Drug Resistance; Granulocyte Colony-Stimulating Factor; Humans; Karyotyping; Leukocyte Count; Male; Monosomy; Myelodysplastic Syndromes | 1994 |
[Complete remission by cytarabine ocfosfate plus G-CSF therapy in a patient with hypoplastic RAEB-T].
Topics: Administration, Oral; Aged; Anemia, Refractory, with Excess of Blasts; Arabinonucleotides; Cytidine Monophosphate; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Male; Prodrugs; Remission Induction | 1995 |
Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arabinonucleotides; Colorectal Neoplasms; Cytidine Monophosphate; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Mice; Mice, Nude; Stomach Neoplasms; Transplantation, Heterologous | 1995 |
[Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes | 1995 |
[Low-dose cytarabine ocfosfate therapy in an elderly acute myelogenous leukemia].
Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Bone Marrow; Cell Count; Cytidine Monophosphate; Drug Administration Schedule; Humans; Leukemia, Myelomonocytic, Acute; Male | 1995 |
[Refractory anemia with excess myeloblast in transformation induced remission by combined oral administration of cytarabine ocfosfate and 6-mercaptopurine].
Topics: Administration, Oral; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Female; Humans; Mercaptopurine; Middle Aged; Remission Induction | 1995 |
Highly sensitive high-performance liquid chromatographic assay for 1-beta-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate).
Topics: Antineoplastic Agents; Arabinonucleotides; Chromatography, High Pressure Liquid; Cytidine Monophosphate; Drug Stability; Humans; Reproducibility of Results | 1995 |
[Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate].
Topics: Acute Disease; Administration, Oral; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Female; Humans; Leukemia; Middle Aged | 1995 |
[Successful treatment of acute myelomonocytic leukemia developed from MDS with cytarabine ocfosfate (SPAC)].
Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukemia, Myelomonocytic, Acute; Myelodysplastic Syndromes; Remission Induction | 1995 |
[Successful treatment of myelodysplastic syndrome with cytarabine ocfosfate].
Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Humans; Male; Myelodysplastic Syndromes; Remission Induction | 1994 |
[Hypoplastic leukemia successfully treated by oral administration with cytarabine ocfosfate].
Topics: Administration, Oral; Aged; Arabinonucleotides; Blood Cell Count; Bone Marrow Cells; Cytidine Monophosphate; Humans; Leukemia; Male; Remission Induction | 1994 |
[Therapy-related acute non-lymphocytic leukemia (M2) with 7;11 chromosome translocation induced into complete remission by low dose cytosine arabinoside and cytarabine ocfosfate therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 7; Cytarabine; Cytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Remission Induction; Translocation, Genetic | 1994 |
[Successful treatment of acute myelogenous leukemia in an elderly patient with cytarabine ocfosfate].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arabinonucleotides; Cerebral Infarction; Cytidine Monophosphate; Dementia, Vascular; Female; Humans; Leukemia, Myeloid, Acute; Remission Induction | 1994 |
Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Topics: Acute Disease; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Polycythemia Vera | 1994 |
Combined oral administration of etoposide and arabinofuranosylcytosine-5'-stearylphosphate enhances the antitumor effect against P388 ascites tumors.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Etoposide; Leukemia P388; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Time Factors; Treatment Outcome | 1994 |
[A new antileukemic drug, cytarabine ocfosfate].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Dogs; Female; Humans; Leukemia, Experimental; Leukemia, Promyelocytic, Acute; Male; Mice; Prodrugs; Rats; Tumor Cells, Cultured | 1993 |
[Clinical efficacy of YNK 01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) in patients with polycythemia vera].
Topics: Adult; Aged; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Hemoglobins; Humans; Male; Middle Aged; Polycythemia Vera | 1993 |
[Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1996 |
Combination therapy with granulocyte colony-stimulating factor, all-trans retinoic acid, and low-dose cytotoxic drugs for acute myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Bone Marrow; Cyclophosphamide; Cytidine Monophosphate; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Tretinoin | 1995 |
A patient with basophilic-eosinophilic myeloproliferative disorder showing monosomy 7 and hyperhistaminemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arabinonucleotides; Basophils; Chromosomes, Human, Pair 7; Cytidine Monophosphate; Eosinophilia; Histamine; Humans; Karyotyping; Male; Monosomy; Myeloproliferative Disorders; Prednisolone | 1997 |
[Oral administration of cytarabine ocfosfate and ondansetron hydrochloride in patients with acute myeloid leukemia who can not be treated with intensive chemotherapy:--attempt to make their quality of life better].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Ondansetron; Quality of Life | 1998 |
Continuous oral cytarabine ocfosfate with interferon-alpha-2b for patients with newly diagnosed chronic myeloid leukaemia: a pilot study.
Topics: Adolescent; Adult; Aged; Arabinonucleotides; Cytidine Monophosphate; Female; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Treatment Outcome | 2001 |
Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Blast Crisis; Bone Marrow; Cytidine Monophosphate; Cytogenetic Analysis; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction | 2002 |
Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cryptogenic Organizing Pneumonia; Cytidine Monophosphate; Fatal Outcome; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Male; Radiography, Thoracic; Tomography, X-Ray Computed | 2004 |
Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Bone Marrow Transplantation; Brain; Chromosome Inversion; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cytidine Monophosphate; Dysarthria; Fatal Outcome; Humans; Hydroxyurea; Hyperesthesia; Janus Kinase 2; Leukemia, Neutrophilic, Chronic; Leukemic Infiltration; Male; Middle Aged; Neoplasm Proteins; Recurrence; Transplantation, Homologous | 2007 |
Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Treatment Outcome | 2013 |
Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate.
Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction | 2015 |